Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for Apellis Pharmaceuticals in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush currently has […]
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2 3% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lifted by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on APLS. Robert W. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73), Briefing.com reports. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $92.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 42.97% from the company’s current price. Several […]